Home | BSAAM's Organizer | BSAAM's Sponsor | London Accommodation Info | Contact Us
BSAAM's Anti Ageing Conference London 2019
Follow us on ...
Facebook  Twitter  Instagram
Conference Information
Download 2018 Feedback Form (Required for Credits)
Pre-conference Presentations
2018 Program
2018 Speaker List & Presentation Download
Speaker Videos
2018 Pre-Conference Workshops
2018 Exhibitors
2018 Peer Review Board Members
Delegate Information
2018 VENUE: The Kensington Town Hall - MAP
Nearby London Accommodations
A4M Board Certification
  American Board Of Anti-Aging/Regenerative Medicine (ABAARM)
Past Conference Information
2017 Speakers and Presentations
2017 Programme
2017 Exhibitors

BSAAMs AACL 2017 Peer Review Board Members
2016 Speakers and Presentations
2016 Programme
2016 Exhibitors
2016 Moderators
BSAAMs AACL 2016 Peer Review Board Members
2015 Speakers and Presentations
2015 Programme
2015 Exhibitors
2015 Moderators
BSAAMs AACL 2015 Peer Review Board Members
2014 Speakers and Presentations
2014 Programme
2014 Exhibitors
2014 Moderators
2014 Peer Review Board Members
2014 Aesthetic Peer Review Board Members
2013 Speakers and Presentations
2013 Programme
2013 Exhibitors
2013 Moderators
2013 Peer Review Board Members
2013 Aesthetic Peer Review Board Members
2012 Speakers and Presentations
2012 Programme
2012 Exhibitors
2012 Moderators
2012 Peer Review Board Members
2012 Aesthetic Peer Review Board Members
2011 Speakers and Presentations
2011 Programme
2011 Exhibitors
2011 Moderators
2011 Peer Review Board Members
2011 Aesthetic Peer Review Board Members
2010 Conference Manual
2010 Speakers and Presentations
2010 Programme
2010 Exhibitors
2010 Moderators
2010 Peer Review Board Members
2010 Aesthetic Peer Review Board Members
Programme for the 2009
Exhibitors for the 2009
Speakers for the 2009
2009 Peer Review Board Members
2009 Aesthetic Peer Review Board Members
Programme for 2008
Exhibitors for 2008
Speakers for 2008
2008 Peer Review Board Members
2008 Aesthetic Peer Review Board Members
  2007 Speaker List
2007 Speaker Programme
  Pre Conference Workshops
Sept 12 Pre-Conference Workshop Programme
Sept 13 Pre-Conference Workshop Programme
  2007 Peer Review Board Members
  Exhibitors for 2007
  3rd Annual Anti-Ageing Conference Manual (2006)
  Programme for 2006
  ISRM2006 Scientific Board Members
  2006 Peer Review Board Members
  Exhibitors 2006
  Post Review of 2005
  Remarks about 2005
  Peer Review Board of 2005
  Past Speakers 2005
  Past Speakers 2004
  Past Speakers Monte Carlo 2002
BSAAM's AACL Organizer
BSAAM Affiliates
AACL Supporters
HB Health
  Sun Chlorella

AACL 2012 Speaker

HaqProfessor Syed E A Haq MB BS BSc (HON) PhD DIC MRCP(UK)

Professor Syed Haq, is a Consultant Physician and Founder of The London Preventative Medicine Centre. He is the Clinical and Scientific Director of Daval International Ltd., a biopharmaceutical company developing a platform for the treatment of autoimmune (e.g., Systemic Sclerosis), neurodegenerative (e.g., Motor neuron disease, Alzheimer’s disease, Myasthenia Gravis, Multiple Sclerosis) and inflammatory (e.g., Rheumatoid arthritis) diseases using a patented polyclonal antibody/peptide composite which has recently completed two phase II clinical trials in the UK. He has worked and trained at some of the foremost institutions - Guy’s Hospital, Hammersmith and Royal Brompton Hospitals, Imperial College, Massachusetts General Hospital, Harvard Medical School, and Tufts University, New England Medical Center Hospitals Inc.

Prof. Haq has published peer-reviewed articles in several internationally renowned scientific journals including PNAS and Nature Medicine. He has been co-chairman of the Anti-ageing Conference London (2008-11), and has been an invited presenter/speaker at numerous international conferences (American Heart Association, American College of Cardiology, Anti-Ageing Medicine World Congress and the NCD National Workshop, India). Prof. Haq has received several national and international awards/fellowships from the Medical Research Council, Wellcome Trust International, American Heart Association, Astra Zeneca and the Heart Failure Society of America.

2012 - A novel monotherapy hyperimmune caprine sera in the treatment of pathological fibrosis/vasculopathy and neurological disease implications for anti-ageing

Pathological fibrosis - Systemic sclerosis (scleroderma, SSc) is a multi-systemic disease characterised clinically by fibrosis of the skin, joints, muscles and internal organs. The pathogenesis of SSc remains incompletely understood although it seems likely that there is an interplay between inflammatory, vascular (vasculopathy) and fibroblast dysfunction, leading ultimately to the sustained activation of a population of fibroblasts that deposit increased amounts of extracellular matrix in lesional tissues, including the skin and internal organs.

Impairment of the immune system is currently thought to play an important role in this condition. This is based on the observation that in the early phases of SSc, mononuclear cells migrate to the dermis and accumulate around small blood vessels, nerves and skin appendages. Furthermore, there is a direct relationship between the extent of cutaneous inflammation and the extent and progression of fibrosis of the skin. Stimulated T-lymphocytes of patients with SSc produce more tumour necrosis factor-alpha (TNF-a), interleukin-1 and -2 compared with healthy controls and the serum concentrations of IL-2, IL-4, IL-6 and IL-8 and soluble IL-2receptors are elevated. The occurrence of autoantibodies, predominantly anti-topoisomerase-1 (ATA) and anti-centromere antibodies (ACA), in approximately 90% of the patients, points to an alteration of the humoral immune system.

At present, no treatment has been definitely shown to be effective in SSc. Because of its presumed immunologic pathogenesis, modulation of the immune system has been the major goal in therapeutic interventions in SSc. Several studies have reported effectiveness of immune modulating drugs in the treatment of this disease, although these have mostly been in open, uncontrolled trials. These drugs include azathioprine, cyclosporin, methotrexate and cyclophosphamide. Amongst these, methotrexate and cyclophosphamide are currently the most widely used. New, more specific immunological treatment modalities have been harnessed in order to improve the treatment and prognosis of scleroderma patients. In 2005, a patient with systemic sclerosis was treated with hyperimmune caprine sera on a compassionate use basis with a sustained improvement in mobility and, in particular, there was an improvement in proximal muscle power and skin characteristics. As a result we embarked on a 1-year phase II Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of a hyperimmune caprine serum given as a monotherapy to patients with Late Stage Established Diffuse Cutaneous Systemic Sclerosis (diffuse scleroderma). The results of this trial will be discussed together with open-label studies, which looked at neurological diseases in the form of demyelinating and/or axonal damage and Alzheimer’s disease. The implications of these findings in anti-ageing therapeutics will be discussed.


Home | BSAAM's Organizer | BSAAM's Sponsor | London Accommodation Info | Contact Us
BSAAM's Anti Ageing Conference London, 38 Regent on the River
William Morris Way London SW6 2UT, United Kingdom
Tel: +44 (0)79 7317 3478  Fax: +44 (0)20 7491 0410
Emails :